title: Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids.
abstract: Immunomodulatory effects of endogenous and exogenous cannabinoids have been investigated in numerous studies, mostly performed with isolated cells or transformed cell lines, but only sparse data exist on human polymorphonuclear neutrophils (PMNs). We therefore investigated the respiratory burst reaction of human whole-blood PMNs under the influence of cannabinoids using flow cytometry. In their natural whole-blood milieu, a CB(2) receptor-dependent stimulation of the PMN respiratory burst was found at nanomolar concentrations of CP55 940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol] and methanandamide after a 3-h incubation period, whereas the short-living and rapidly hydrolyzed endogenous ligand anandamide did not alter the burst reaction of whole-blood PMNs under the same experimental conditions. The stimulatory cannabinoid effect was totally absent in isolated PMNs but could be transferred onto isolated PMNs by adding the cell-free low-molecular mass plasma fraction (<5000 Da) of cannabinoid-incubated blood, indicating an indirect mechanism depending on humoral products or mediators. Results of our further experiments suggest that products of the arachidonic acid metabolism are mediators of the cannabinoid-induced enhancement of the respiratory burst reaction of whole-blood PMNs.
authors.affiliation: Department of Anesthesiology and Intensive Care Medicine (B), Medical University of Vienna, Austria. birgit.kraft@meduniwien.ac.at
authors.forename: Birgit
authors.initials: B
authors.lastname: Kraft
authors.forename: Hans G
authors.initials: HG
authors.lastname: Kress
mesh_terms: D001095:Arachidonic Acids / Q000494:pharmacology; D002186:Cannabinoids / Q000494:pharmacology*; D003511:Cyclohexanols / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D063388:Endocannabinoids; D006801:Humans; D066298:In Vitro Techniques; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D053284:Polyunsaturated Alkamides; D017382:Reactive Oxygen Species / Q000097:blood; D043885:Receptor, Cannabinoid, CB2 / Q000187:drug effects*; D016897:Respiratory Burst / Q000187:drug effects; D013268:Stimulation, Chemical
chemical_list: D001095:Arachidonic Acids; D002186:Cannabinoids; D003511:Cyclohexanols; D016861:Cyclooxygenase Inhibitors; D063388:Endocannabinoids; D016859:Lipoxygenase Inhibitors; D053284:Polyunsaturated Alkamides; D017382:Reactive Oxygen Species; D043885:Receptor, Cannabinoid, CB2; C088155:methanandamide; D009240:N-Formylmethionine Leucyl-Phenylalanine; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; C078814:anandamide